Catalog No.
DHA42301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa-lambda
Clonality
Monoclonal
Target
Vascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A, ANG-2, ANGPT2, Angiopoietin-2
Concentration
11.9 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P15692 & O15123
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
20mM His, 140 mM NaCl, pH6.0
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
Bispecific, RG7716, RO6867461, CAS: 1607793-29-2
Clone ID
Faricimab
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial, PMID: 30905643
Efficacy of Every Four Monthly and Quarterly Dosing of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The STAIRWAY Phase 2 Randomized Clinical Trial, PMID: 32729897
Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial, PMID: 32729888
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases, PMID: 33471572
Targeting Angiopoietin in Retinal Vascular Diseases: A Literature Review and Summary of Clinical Trials Involving Faricimab, PMID: 32785136
Faricimab: expanding horizon beyond VEGF, PMID: 31695160
Antibodies to watch in 2021, PMID: 33459118
Faricimab Combination Therapy for Sustained Efficacy in Neovascular Age-Related Macular Degeneration, PMID: 32729885
New therapeutic targets in the treatment of age-related macular degeneration, PMID: 31787390
Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease, PMID: 31513439
Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020, PMID: 32511123
Innovative therapies for neovascular age-related macular degeneration, PMID: 31298960
Emerging drugs for the treatment of diabetic retinopathy, PMID: 32715794
New Anti-VEGF Drugs in Ophthalmology, PMID: 32342814
The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye, PMID: 33072401
Longer-acting treatments for neovascular age-related macular degeneration-present and future, PMID: 33432165
Wet age-related macular degeneration: treatment advances to reduce the injection burden, PMID: 32479026
Faricimab: Two in the Bush Is Proving Better than One in the Hand?, PMID: 34242102
Evolving treatment paradigms for PCV, PMID: 34262165
Next-generation anti-VEGF agents for diabetic macular oedema, PMID: 34373607
HIGHLIGHTS OF ADVANCES IN MEDICAL RETINA FROM THE VIRTUAL WORLD OPHTHALMOLOGY CONGRESS 2020, PMID: 33499644
Vascular Endothelial Growth Factor Antagonists: Promising Players in the Treatment of Neovascular Age-Related Macular Degeneration, PMID: 34188445
Development and evaluation of an ultrasensitive free VEGF-A immunoassay for analysis of human aqueous humor, PMID: 31070047
Molecular Features of Classic Retinal Drugs, Retinal Therapeutic Targets and Emerging Treatments, PMID: 34371793
Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review, PMID: 33962696
For research use only. Not for human or drug use.
